Inclusion Criteria:

- Patient is 18 years of age or older

- Patient has an established diagnosis of multiple myeloma based on myeloma diagnostic
criteria

- Patient must have adequate organ function

- Patient is refractory to prior bortezomib regimen and have also been exposed to prior
IMiD (thalidimide or lenalidmide)

- Patient has relapsed and refractory multiple myeloma after at lest 2 prior treatment
regimens

- Patient is relapsed, refractory, intolerant, and/or ineligible (in the opinion of the
investigator) to other therapies including an IMiD (thalidomide OR lenalidomide)

- Patient is refractory to bortezomib (no response on prior bortezomib containing
regimen or progression on or within 60 days of bortezomib containing regimen

Exclusion Criteria:

- Patient has known hypersensitivity to any components of bortezomib or vorinostat

- Patient has had a prior allogeneic bone marrow transplant or plans to undergo any
type of bone marrow transplantation within 4 weeks of the initiation of study therapy

- Patient has known hypersensitivity to any components of bortezomib or vorinostat

- Patient has active Hepatitis B or C, plasma cell leukemia, or is HIV positive